Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZX1305 (recombinant human nerve growth factor) in traumatic optic nerve injury – Phase II
CTR20230387Phase 2Active
- Sponsor
- Jiangsu Zhongxin Pharmaceutical
- Start
- Jun 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SMR001 in Optic neuropathies (2 arms), sponsored by Jiangsu Zhongxin Pharmaceutical. Primary endpoint: Change in best-corrected visual acuity (BCVA) from baseline at 2 and 4 weeks after first injection. Started Jun 2023; status: active.
02
Drugs
SMR001
03
Conditions
Optic neuropathies
Beyond the preview
Go deeper on CTR20230387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230387.